Altogether, these data support a model whereby COX-2 inhibition, by altering the inflammatory properties of CTX-treated cancer cells, limits the recruitment of myeloid cells, favors T cell effector function and thereby immune-mediated tumor control when in combination with both CTX and ICB. The gene discussed is PTGS2; the disease is neoplasm.